Abstract
Get full access to this article
View all access options for this article.
References
1.
Cluff
LE
Caranasos
G
Stewart
RB
. Clinical problems with drugs . Philadelphia, PA : WB Saunders , 1975 .
2.
Stewart
RB
Philp
J
Cluff
LE
. Drug monitoring: a requirement for responsible drug use . Baltimore, MD : Williams and Wilkins , 1977 .
3.
Hale
WE
Marks
RG
Stewart
RB
. The Dunedin program: a Florida geriatric screening process: design and initial data . J Am Geriatr Soc
1980 ; 27 : 377 –80 .
4.
Borden
EK
. Post-marketing surveillance: drug epidemiology . J Int Med Res
1981 ; 9 : 401 –7 .
5.
Cohen
MR
. A compilation of abstracts and index published by the Boston Collaborative Drug Surveillance Program, 1966–1985 . Hosp Pharm
1986 ; 21 : 497 –559 .
6.
Brolund
GV
. The FDA adverse reaction report data base . Drug Inf J
1985 ; 19 : 299 –303 .
7.
Tilson
HH
. Methodologic issues in post-marketing surveillance—pharmaceutical industry's view . Drug Inf J
1985 ; 19 : 275 –83 .
8.
Jones
JK
. Post-marketing surveillance, annual reports and long-term follow-up . Drug Inf J
1982 ; 16 : 87 –92 .
9.
Strom
BL
Melmon
KL
Miettinen
OS
. Post-marketing studies of drug efficacy . Arch Intern Med
1985 ; 145 : 1791 –4 .
10.
Morse
ML
. The COMPASS data base . Drug Inf J
1985 ; 19 : 249 –52 .
11.
Tilson
HH
Wisnant
J
. Pharmacoepidemiology-drugs, arthritis, and neoplasms: industry contribution to the data . Am J Med
1985 ; 78 : 69 –76 .